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Abstract
Background: No unified method exists to effectively predict and monitor progression of pulmonary arterial
hypertension (PAH). We assessed the longitudinal relationship between a novel marker of cardiopulmonary
reserve and established prognostic surrogate markers in patients with pulmonary vascular disease.
Methods and Results: Twenty participants with confirmed (n = 14) or at high risk (n = 6) for PAH underwent
cardiovascular magnetic resonance (CMR) at baseline and after ~6 months of guideline-appropriate
management. Ten PAH participants underwent RHC within 48 h of each CMR. RHC (mean pulmonary arterial
pressure, mPAP; pulmonary vascular resistance index, PVRI; cardiac index, CI) and phase-contrast CMR (mean pulmonary
arterial blood flow velocity, meanPAvel) measurements were taken at rest and during continuous adenosine infusion
(70/140/210 mcg/kg/min). Initial meanPAvel’s (rest and hyperemic) were correlated with validated surrogate prognostic
parameters (CMR: RV ejection fraction, RVEF; RV end systolic volume indexed, RVESVI; RHC: PVRI, CI; biomarker: NT-pro
brain natriuretic peptide, NTpBNP; clinical: 6-min walk distance, 6MWD), a measure of pulmonary arterial stiffness
(elastic modulus) and volumetric estimation of RV ventriculoarterial (VA) coupling. Changes in meanPAvel’s were
correlated with changes in comparator parameters over time.
At initial assessment, meanPAvel at rest correlated significantly with PVRI (inversely), CI (positively) and elastic
modulus (inversely) (R2 > 0.37,P < 0.05 for all), whereas meanPAvel at peak hyperemia correlated significantly
with PVRI, RVEF, RVESVI, 6MWD, elastic modulus and VA coupling (R2 > 0.30,P < 0.05 for all). Neither resting or
hyperemia-derived meanPAvel correlated with NTpBNP levels. Initial meanPAvel at rest correlated significantly
with RVEF, RVESVI, CI and VA coupling at follow up assessment (R2 > 0.2,P < 0.05 for all) and initial meanPAvel
at peak hyperemia correlated with RVEF, RVESVI, PVRI and VA coupling (R2 > 0.37,P < 0.05 for all). Change in
meanPAvel at rest over time did not show statistically significant correlation with change in prognostic
parameters, while change in meanPAvel at peak hyperemia did show a significant relationship with ΔRVEF,
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ΔRVESVI, ΔNTpBNP and ΔCI (R2 > 0.24,P < 0.05 for all).
Conclusion: MeanPAvel during peak hyperemia correlated with invasive, non-invasive and clinical prognostic
parameters at different time points. Further studies with predefined clinical endpoints are required to evaluated if this
novel tool is a marker of disease progression in patients with pulmonary vascular disease.
Background
Pulmonary arterial hypertension (PAH) is characterised
by a pathological increase in the resistance of the pul-
monary circulation secondary to arterial wall remodel-
ling, vasoconstriction and in situ thrombosis (pulmonary
vascular disease, PVD). Progressive obliteration of the
pulmonary vascular bed eventually leads to right ven-
tricular (RV) failure and premature death. Therapeutic
advances have contributed to better long-term outcomes
but disease progression remains difficult to predict and
objectively monitor necessitating new methods.
We previously demonstrated proof-of-concept for a
novel non-invasive method to assess ‘cardiopulmonary
reserve’ as it pertains to PAH by measuring the average
pulmonary arterial blood flow velocity (meanPAvel) at
rest and during standardised intravenous (IV) adenosine
infusion using phase-contrast cardiovascular magnetic
resonance (CMR) [1]. This approach to ‘stressing’ the
cardiopulmonary unit, whilst novel, was feasible, safe
and simple, with the results confirming that meanPAvel
at peak hyperemia was an excellent functional correlate
for cardiopulmonary reserve across a range of clinical
risk phenotypes.
As a marker of cardiopulmonary reserve and with the
advantage of ameliorating the impact of unrelated sys-
temic processes on variables measured at rest, we
hypothesised that meanPAvel at peak hyperemia may
provide prognostic information at initial assessment and
during follow up. To evaluate this, we investigated the
association of meanPAvel at rest and during peak hyper-
aemia with accepted RHC-derived, CMR-derived, bio-
marker and clinical prognostic surrogate markers in a
cohort of patients with confirmed PAH or at high risk
for incident PAH. Specifically, we hypothesised that rela-
tive to meanPAvel at rest, meanPAvel at peak hyper-
aemia at initial assessment would be more closely
associated with comparator parameters at initial and
follow-up assessments, and that changes in meanPAvel
at peak hyperemia would correlate more closely with
changes in these prognostic markers over time.
Methods
We prospectively recruited participants with known or
suspected PAH and a clinical indication for a right heart
catheter (RHC) through a single tertiary-referral centre
over a 14-month period (2013–2014). Patients were
ineligible if they were <18 years old; pregnant; had
known or suspected PAH due to congenital heart disease
with left-to-right shunt, or portopulmonary hyperten-
sion; or, had a contraindication to CMR or IV adenosine.
Right heart catheterization for suspected PAH was deemed
clinically indicated by pulmonary hypertension experts
following a comprehensive review of clinical status and
ancillary investigations, in accordance with guidelines [2].
All participants provided written informed consent and
protocols were approved by the Local Institutional Re-
search Ethics Committee.
At initial assessment, all participants underwent a
RHC and CMR with IV adenosine within 48 h, with
PAH confirmed by hemodynamic criteria (mean pul-
monary arterial pressure, mPAP, >25 mmHg; mean pul-
monary arterial wedge pressure, mPAWP, <15 mmHg;
and pulmonary vascular resistance, PVR >3 Woods
units, WU). Participants with mPAWP > 15 mmHg were
excluded and did not undergo vasoreactive testing.
Patients with PAH were invited to undergo repeat RHC
and CMR with vasoreactivity testing and participants
with suspected but excluded PAH (high-risk for incident
PAH) invited to undergo repeat CMR with vasoreative
testing approximately 6 months after their initial study.
Between assessments, patients were administered
guideline-appropriate management.
Right heart catheterization was performed via the right
femoral vein with a 7 F Swan-Ganz thermodilution pul-
monary artery catheter (Edwards Lifesciences, California,
USA). Systemic arterial pressures were monitored by arm
cuff. Complete resting hemodynamic assessment was per-
formed in accordance with current guidelines. Intravenous
(IV) adenosine (Adenoscan, 3 mg/mL, Astellas Pharma,
Tokyo, Japan) was infused via peripheral vein at three
increasing doses: 70-, 140-, and 210mcg/kg/min, and re-
peat hemodynamic assessment (mPAP/mPAWP/CI/PVR)
conducted after a minimum of two minutes’ infusion at
each dose.
CMR was performed with a 1.5 T magnet (Magnetom,
Siemens, Erlangen, Germany) with images obtained at
end-expiration. Volumetric and functional analyses were
performed using steady-state free procession (SSFP) se-
quences of the atria and ventricles. Flow imaging through
the main pulmonary artery was performed 1.5-2 cm above
the pulmonary valve using a velocity-encoded gradient
echo sequence with an upper velocity limit of 150 cm/s,
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temporal resolution of 39 ms and spatial resolution of
1.8x1.8x6mm (Fig. 1). Adenosine was infused using the
same protocol as during RHC, with flow imaging through
the pulmonary trunk repeated after a minimum of 2 min
at each adenosine dose. Analyses were performed offline
using specialized software (CMR42, Circle Cardiovascular
Imaging Inc., Calgary, Canada). Ventricular endocardial
and epicardial contours were manually outlined at end-
diastole and end-systole to permit calculation of ventricu-
lar volumes and myocardial mass by Simpson’s method.
Blood flow through the pulmonary trunk was measured
by outlining the endovascular border at all 20 recon-
structed cardiac phases permitting calculation of mean
pulmonary arterial blood flow velocity (meanPAvel), elas-
tic modulus (pulse pressure x minA/(maxA-minA)) and a
volumetric estimation of ventriculoarterial (VA) coupling
(RVESV/RV stroke volume) [3]. All participants under-
went 6-min walk tests and had blood samples taken for
NT-proBNP quantification, which was centrifuged within
1 h for 10 min at 2800 rpm, and stored at −80 °C until
analysis using an ELISA kit (USCN Life Science, Texas,
USA).
Treatment Strategy
The objective was to assess the relative strength of asso-
ciation of meanPAvel measured at rest and at peak
hyperemia with comparator surrogate prognostic param-
eters. Treatment of participants with PAH was at the
discretion of treating physicians and in line with current
guidelines [4].
Comparator Surrogate Prognostic Parameters
Comparator surrogate prognostic parameters for initial
and serial analyses were defined a priori as: 1) CMR-
derived: right ventricular ejection fraction (RVEF) and
right ventricular end systolic volume index (RVESVI); 2)
Biomarker: NT-proBNP levels; 3) RHC-derived: pul-
monary vascular resistance index (PVRI) and cardiac
index (CI); 4) Clinical: six-minute walk distance
(6MWD). In addition to these validated serial prognos-
tic parameters, two other physiologically-relevant pa-
rameters were assessed: a marker of pulmonary arterial
stiffness (elastic modulus; at initial assessment only),
and volumetric estimation of VA coupling (at initial
and follow-up assessments).
Statistical Analysis
Normally distributed continuous variables were expressed
as means ± standard deviations. Normality was assessed
using the Shapiro-Wilk normality test. Scatterplots of
univariate associations were reviewed and, where ap-
propriate, Pearson correlation coefficients were used to
explore the strength of linear relationships between
meanPAvel at rest and during hyperemia with compara-
tor prognostic parameters and Spearman correlation
coefficients were used to explore the strength of rela-
tionships that were curvilinear and where there was a
significant departure from a Gaussian distribution.
More specifically, meanPAvel measured at rest and
during hyperemia at the initial assessment were corre-
lated with initial and follow up comparator parameters;
and changes in meanPAvel at rest and during hyperemia
were correlated with changes in comparator parameters
between initial assessment and follow up. Statistical
analyses were performed using a software package
(GraphPad Prism version 6.0, San Diego, California,
USA), with a two-sided P value of <0.05 considered sta-
tistically significant.
Results
Thirty-one participants were recruited (PAH n = 19; sus-
pected but excluded PAH: ‘High Risk’ n = 12) of which 5
were ineligible (mPAWP> 15 mmHg n = 4; claustrophobia
n = 1). 20 underwent repeat investigations (PAH n = 14;
High Risk n = 6) after a median period of 8 months and
21 days (loss to follow-up in PAH group: death from RV
failure n = 1; geographical relocation n = 1; declined n = 1,
and High Risk group: geographical relocation n = 2; inter-
current illness n = 1) and were included in the present
study. Ten of the 14 PAH participants had both repeat
CMR and RHC and 4 had CMR only (declined repeat
RHC n = 4). Demographic and clinical characteristics of
participants are presented in Table 1, with suspected but
excluded PAH participants considered high risk for inci-
dent PAH on the basis of the high prevalence of connective
tissue disease, unaccounted for exertional breathlessness
with disproportionately reduced lung diffusing capacity, el-
evated NTpBNP levels in the absence of left ventricular
Fig. 1 Reference sequences for main pulmonary arterial (MPA) phase
contrast imaging were two double-oblique orthogonal views along
the main axis of the pulmonary trunk (a). The endocardial border of
the MPA was manually outlined at all 20 reconstructed cardiac phases
(b and c) permitting flow velocity profiles to be generated at rest and
hyperemia (d and e respectively: flow velocity in ml/s on y axis and
time in milliseconds on x axis). MeanPAvel was calculated as the
average blood flow velocity across all cardiac phases. Ao = aorta,
RV = right ventricle, RVOT = right ventricular outflow tract
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myocardial disease or renal dysfunction, elevated estimated
pulmonary arterial systolic pressure by transthoracic echo-
cardiography >40 mmHg (n = 6) and ‘borderline’ abnormal
resting hemodynamics (n = 2 with rest mPAP of 21-
24 mmHg) [5].
Mean absolute values of comparator, investigational
and other relevant parameters, and their relative changes
over time, are summarised in Table 2.
Response to adenosine
The hemodynamic and meanPAvel changes in response
to adenosine are shown in Figs. 1 and 2. Systemic blood
pressure (SBP) did not change significantly during ad-
enosine (systolic SBP −6 ± 13 and 0 ± 18% for PAH and
High Risk groups respectively, P = 0.38 and 0.23 respect-
ively – not displayed graphically). There was minimal
intra-observer and interobserver variability for meanPA-
vel measures (mean bias: −0.01 and −0.0000238; 95%
limits of agreement: −0.21–0.19 and −0.27–0.27 respect-
ively) at all doses.
Correlation between mean pulmonary arterial blood flow
velocities and prognostic parameters measured at initial
assessment
Correlation coefficients are presented in Table 3. Mean-
PAvel at rest showed strong positive correlation with CI
and very strong negative correlation (curvilinear) with
PVRI. There was moderate but statistically insignificant
correlation with CMR indices (negative with RVESVI
and positive with RVEF, Fig. 3) and 6MWD (positive),
but no correlation with NTpBNP. Elastic modulus, a
measure of the pressure change required to drive a rela-
tive change in the PA lumen size, showed strong nega-
tive correlation with meanPAvel at rest. Volumetric
estimation of ventriculoarterial coupling showed moder-
ate strength negative correlation with meanPAvel at rest.
Therefore a high effective arterial elastance:maximal sys-
tolic elastance ratio (estimated here by CMR-derived
RVESV/RVSV), suggestive of RV-pulmonary uncoupling,
was associated with lower meanPAvels. Relative to
meanPAvel at rest, meanPAvel at hyperemia correlated
more closely with all parameters except RHC-derived CI
at rest and NTpBNP.
Given the weaker association between CI and mean-
PAvel at peak hyperemia, compared to meanPAvel at
rest, we assessed the relationship between meanPAvel’s and
hemodynamic measurements made during hyperemia. In
this regard, meanPAvel at rest and during hyperemia corre-
lated closely with the maximum CI (R = 0.60, P = 0.005 and
R = 0.65, P = 0.002 respectively) and minimum PVRI (R =
−0.67, P = 0.001 and R = −0.74, P = 0.0002 respectively) dur-
ing adenosine challenge. This is consistent with earlier
work demonstrating close correlation between meanPAvel
and invasively-derived hemodynamics at rest and during
adenosine infusion [1].
Correlation between initial mean pulmonary arterial
blood flow velocities and follow up prognostic
parameters
MeanPAvel measured at rest showed moderate strength
statistically significant correlation with RVEF (Fig. 3),
RVESVI and VA coupling at follow up. Strong negative
correlation with follow up PVRI and positive correlation
with follow up CI were found. In contrast, there was
weak and statistically insignificant correlation with
follow up NTpBNP levels and no correlation with
6MWD. MeanPAvel measured during peak hyperemia
correlated more closely with all parameters except
resting CI (R = 0.67 vs. 0.59 for meanPAvel at rest vs.
peak hyperemia), 6MWD and NTpBNP. Correlation
coefficients are presented in Table 4.
Correlation between changes in mean pulmonary arterial
blood flow velocities and changes in comparator
prognostic parameters
There were no statistically significant associations between
change in meanPAvel measured at rest and change in
comparator prognostic parameters, although statistical
power was reduced with regard to RHC-derived parame-
ters owing to fewer follow-up invasive procedures (n = 14
Table 1 Demographic and clinical characteristics of participants
PAH High risk P value
Participants, n 14 6
Female (%) 11 (79) 5 (83) 0.98
Age, years 54 ± 14 63 ± 7.6 0.18





Diabetes mellitus 2 (14) 0 (0) <0.05
Smoker 1 (12) 0 (0) <0.05
CTD 5 (36) 5 (83) <0.05
NYHA functional class (%)
II 3 (21) 6 (100) <0.05
III 11 (79) 0 (0) <0.05
Therapy, initial/follow-up (%)
Phosphodiesterase-5 inhibitor 1 (7)/0 (0)
Combination 13 (93)/14 (100)
Creatinine, μmol/L 84 ± 21 83 ± 34 0.96
DLCO, % 55 ± 15 58 ± 19 0.76
%FVC/%DLCO 1.41 ± 0.41 1.38 ± 0.27 0.92
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vs. n = 10). In contrast, change in meanPAvel measured at
hyperemia correlated moderate-strongly with all compara-
tor prognostic parameters except 6MWD, PVRI and VA
coupling (R = 0.30, P = 0.30/R = −0.39, P = 0.27/R = −0.44,
P = 0.06 respectively). Similar trends were seen when only
confirmed PAH participants were analysed. Correlation
coefficients are presented in Table 5.
Despite its routine use, 6MWD has many limitations
as a serial prognostic marker (e.g. day-to-day variation,
learning effect and comorbidities), with registry data
showing a decline in 6MWD confers a worse prognosis
but a rise in 6MWD has no impact on survival [6]. In
those participants with a decline in 6MWD (N = 9) in
the present study, correlation with change in meanPAvel
at hyperemia improved but statistical significance was
not met (R = −0.52, P = 0.22) possibly due to the low
sample size.
Discussion
Blood flow velocity through the main pulmonary artery
is thought to decline in PAH due to impeded passage of
cardiac output through remodelled microcirculation,
dilation of proximal pulmonary vessels and eventually,
impaired RV function [7]. Not surprisingly therefore,
mean pulmonary arterial blood flow velocity (meanPAvel)
measured at rest has been shown to correlate with mea-
sures of RV function, arterial load and exercise capacity,
which are all important determinants of prognosis in PAH
[7–11]. This study adds to our knowledge by demonstrat-
ing correlation between our non-invasive measure of ‘car-
diopulmonary’ reserve (meanPAvel at peak hyperemia,
[1]) and validated invasively and non-invasively derived
surrogate prognostic markers at baseline and six month
follow-up. This marker was superior to meanPAvel when
measured at rest. This data would support further studies
being undertaken with hard clinical endpoints, to establish
if this novel marker would provide incremental prognostic
information in patients with PAH or at high risk for
incident PAH.
PAH is principally defined by the plexogenic
pulmonary vasculopathy that underlies its genesis, in-
creasing RV afterload and stress. These two compart-
ments (the RV and pulmonary vasculature) are
integrally related and not surprisingly therefore, mea-
sures of RV afterload (static e.g. PVR, and oscillatory
e.g. pulmonary arterial stiffness, components), stress (e.g.
Table 2 Absolute values and relative change in comparator (bold text) and investigational parameters (mean ± SD)
Parameter Group Initial Follow-up Change (%)
CMR-derived RVEF (%) PAH 41 ± 17 43 ± 13 18 ± 47
High risk 60 ± 7 59 ± 6 −1 ± 13
RVESVI (ml/m2) PAH 50 ± 26 54 ± 25 17 ± 49
High risk 24 ± 7 25 ± 8 4 ± 19
meanPAvel at rest (cm/s) PAH 9.7 ± 2.3 10.0 ± 3.0 5 ± 27
High risk 14.4 ± 2.6 13.9 ± 3.6 −4 ± 23
meanPAvel during hyperemia (cm/s) PAH 12.2 ± 3.3 12.9 ± 6.3 6 ± 32
High risk 21.5 ± 4.3 19.8 ± 4.9 −8 ± 8
RVEDVI (ml/m2) PAH 84 ± 19 91 ± 22 8 ± 15
High risk 61 ± 14 61 ± 17 0 ± 13
LVEF (%) PAH 65 ± 11 68 ± 9 5 ± 21
High risk 69 ± 4 66 ± 6 −3 ± 9
RHC-derived CI (L/min/m2) PAH 2.35 ± 0.76 2.59 ± 0.81 13 ± 19
High risk 2.80 ± 0.55 n/a n/a
PVRI (WU/m2) PAH 5.5 ± 3.2 5.3 ± 3.4 11 ± 47
High risk 1.0 ± 0.4 n/a n/a
mPAP (mmHg) PAH 46 ± 16 48 ± 14 9 ± 24
High risk 19 ± 4 n/a n/a
mPAWP (mmHg) PAH 10 ± 2 8 ± 5 3 ± 30
High risk 10 ± 3 n/a n/a
Clinical/Biomarker NTpBNP (pg/ml) PAH 2310 ± 1354 2740 ± 1361 71 ± 200
High risk 1345 ± 718 1289 ± 693 −3 ± 13
6MWD (m) PAH 421 ± 81 435 ± 62 7 ± 18
High risk 484 ± 71 437 ± 94 −3 ± 8
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NTpBNP), and functional adaptation (e.g. RVEF, RVESVI)
all provide independent prognostic information. In isola-
tion however, each parameter tends to provide a limited
picture of the state of the ‘cardiopulmonary’ unit as a
whole. In our study, meanPAvel at peak hyperemia corre-
lated significantly with measures of RV afterload (e.g. PVRI
and elastic modulus), RV functional adaptation (e.g.
RVEF/RVESVI) and VA coupling (defined as the ratio of
maximal systolic RV elastance: effective arterial elastance),
suggesting a capacity to simultaneously interrogate the
pulmonary vasculature, the RV, and their interaction in a
simple, non-invasive fashion. The capacity to assess the
RV and pulmonary vasculature as a collective unit may
translate to improved ability to discriminate changes in
ventricular function, arterial load, or both when compared
to, for example, RVEF, a serial CMR measure that conveys
consistent prognostic information in PAH patients [3, 12,
13].
Fig. 2 Changes in RHC-derived hemodynamics (panel 1) and CMR-derived meanPAvel (initial assessment, panel 2a; follow-up assessment, panel
2b) in response to adenosine in PAH and High Risk participants. At RHC, intravenous adenosine produced a dose dependent reduction in PVRI
driven predominantly by a higher CI rather than a lower mPAP or transpulmonary gradient (not illustrated). At CMR, these changes were reflected
by a dose-dependent rise in meanPAvel. Changes were more pronounced in High Risk participants relative to those with PAH
Table 3 Correlation coefficients investigating the relationship between meanPAvel and comparator parameters measured during
initial assessment
Comparator parameter meanPAvel at rest P value meanPAvel during hyperemia P value
RVEF 0.43 [−0.01 to 0.74] 0.055 0.66** [0.31 to 0.85] 0.002
RVESVI −0.38 [−0.71 to 0.09] 0.10 −0.70*** [−0.88 to −0.36] 0.0006
NTpBNP −0.19 [−0.61 to 0.30] 0.44 −0.21 [−0.62 to 0.29] 0.40
PVRI −0.81**** [−0.93 to −0.57] <0.0001 −0.88*** [−0.95 to −0.70] <0.0001
CI 0.65** [0.30 to 0.85] 0.002 0.41 [−0.03 to 0.72] 0.07
6MWD 0.43 [−0.04 to 0.74] 0.07 0.58** [0.17 to 0.82] 0.009
Elastic modulus −0.61** [−0.83 to −0.23] 0.004 −0.65** [−0.85 to −0.29] 0.001
VA coupling −0.49* [−0.77 to −0.05] 0.03 −0.75*** [−0.90 to −0.46] 0.0001
Maximum CI 0.60** [0.22 to 0.83] 0.005 0.65** [0.29 to 0.85] 0.002
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‘Traditional’ prognostic parameters are generally mea-
sured at rest and are subject to the influence of unre-
lated systemic factors such as anxiety, hypertension and
sedation which may be compounded by serial assess-
ment. Moreover, they lack the capacity to assess physio-
logical reserve, that is, they provide a static measure of a
dynamic disease process. Our protocol, like other
physiological stress tests, negates the influences of unre-
lated systemic factors whilst permitting assessment of
reserve as it pertains to PAH, that is, the degree of func-
tional pulmonary circulation recruitable by endothelial
independent mechanisms with IV adenosine (‘vascular
reserve’) and the capacity of the RV to increase blood
flow in response to downstream circulatory recruitment
(‘RV reserve’: chronotropic/inotropic). We postulate that
the generally closer association found between meanPA-
vel at peak hyperemia with validated prognostic parame-
ters, compared with meanPAvel measured at rest, was
due to the capacity to assess the cardiopulmonary unit
as whole and its’ reserve while ameliorating the impact
of unrelated systemic processes.
Acknowledging the above, not all validated prognostic
comparators correlated significantly with meanPAvel at
peak hyperemia. Most notably, NTpBNP levels mea-
sured at initial assessment did not correlate with mean-
PAvel measured at the same assessment or at follow-up,
although the relative change in NTpBNP correlated with
the change in meanPAVel at peak hyperemia over time.
Fig. 3 Scatterplots illustrating the relationship between RVEF, meanPAvel at rest and meanPAvel at hyperemia at different time points R = Pearson
correlation coefficient.
Table 4 Correlation coefficients investigating the relationship between meanPAvel measured during initial assessment with follow-up
comparator parameters
Comparator parameter meanPAvel at rest P value meanPAvel during hyperemia P value
RVEF 0.47* [0.04 to 0.76] 0.04 0.72*** [0.41 to 0.88] 0.0003
RVESVI −0.53* [−0.79 to −0.10] 0.02 −0.71*** [−0.88 to −0.37] 0.0005
NTpBNP −0.40 [−0.73 to 0.06] 0.09 −0.42 [−0.73 to 0.04] 0.07
PVRI −0.62* [−0.89 to −0.01] 0.05 −0.70* [−0.92 to −0.15] 0.02
CI 0.67* [0.11 to 0.90] 0.03 0.59 [−0.02 to 0.88] 0.06
6MWD 0.23 [−0.26 to 0.63] 0.34 0.10 [−0.39 to 0.54] 0.71
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Previous studies have demonstrated association between
baseline NTpBNP levels, resting hemodynamics, lung
function, peak VO2 and prognosis, CMR-derived mea-
sures of RV function, and association between change in
NTpBNP over time and survival [14–19]. The discord-
ant findings of strong correlation between meanPAVel at
peak hyperemia, resting hemodynamics and markers of
RV functional adaptation (RVEF, RVESVI) but no correl-
ation with NTpBNP levels in absolute terms were unex-
pected and difficult to explain biologically: they may
therefore reflect a statistical anomaly. A lack of correl-
ation between change in meanPAvel and change in PVRI
over time was likely due to the small sample size under-
going repeat RHC (N = 10) or, as earlier discussed, the
impact of unrelated systemic factors on resting measures
that may compound with serial assessment. No correl-
ation between change in meanPAvel at peak hyperemia
and change in 6MWD over time may reflect the inher-
ent limitations of serial 6MWDs and is in keeping with
registry data showing a decline in 6MWD is prognostic-
ally relevant whereas an increase is not [6]. Closer asso-
ciation between these variables in the subset of patients
that experienced a decline in 6MWD (n = 9: R = 0.59, P
= 0.22) is in keeping with our other findings, acknow-
ledging that statistical significance was not met, likely
due to a small sample size.
Study limitations
The major limitations are the small sample size, single
centre study design, and lack of clinical outcome data.
Findings from this study should be considered hypoth-
esis generating. Repeat vasoreactivity testing via invasive
or non-invasive protocols is novel, with this study de-
signed to explore its potential clinical utility by assessing
relative strength of association across a range of validated
prognostic parameters. Whether meanPAvel provides in-
dependent prognostic information cannot be determined.
Evidence for potential clinical utility of repeat standar-
dised vasoreactivity testing using this protocol is provided
by the combination of physiologically appropriate correl-
ation across a range of relevant CMR-derived, RHC-
derived, biomarker and clinical variables; and correlation
of generally greater strength at hyperemia compared to
rest. Larger studies are required to confirm these findings.
Conclusion
Mean pulmonary arterial blood flow velocity measured
using CMR during non-invasive standardised pulmonary
vasoreactive testing correlated moderate-strongly with a
range of CMR-derived, RHC-derived, biomarker and
clinical prognostic variables at initial assessment and at
follow up. Change in meanPAvel at peak hyperemia on
repeat vasoreactivity testing correlated with change in
these variables over time, although correlation was gener-
ally weaker. Compared with meanPAvel measured at rest,
correlation was generally stronger with meanPAvel mea-
sured at peak hyperemia. The novel parameter of meanPA-
vel at peak hyperemia may provide prognostic information
by simultaneously interrogating the pulmonary vasculature
and RV functional capacity whilst ameliorating the impact
of unrelated systemic processes, although larger trials are
required to confirm these findings.
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Table 5 Correlation coefficients investigating the relationship between changes in meanPAvel and changes in comparator
parameters over time
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